Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties
MetadataShow full item record
Ceramide is a bioactive lipid that plays an important role in stress responses leading to apoptosis, cell growth arrest and differentiation. Ceramide production is due in part to sphingomyelin hydrolysis by sphingomyelinases. In brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increases in its activity and expression have been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Increased nSMase2 activity translates into higher ceramide levels and neuronal cell death, which can be prevented by chemical or genetic inhibition of nSMase2 activity or expression. However, to date, there are no soluble, specific and potent small molecule inhibitor tool compounds for in vivo studies or as a starting point for medicinal chemistry optimization. Moreover, the majority of the known inhibitors were identified using bacterial, bovine or rat nSMase2. In an attempt to identify new inhibitor scaffolds, two activity assays were optimized as screening platform using the recombinant human enzyme. First, active hits were identified using a fluorescence-based high throughput compatible assay. Then, hits were confirmed using a 14C sphingomyelin-based direct activity assay. Pharmacologically active compounds and approved drugs were screened using this strategy which led to the identification of cambinol as a novel uncompetitive nSMase2 inhibitor (Ki = 7 μM). The inhibitory activity of cambinol for nSMase2 was approximately 10-fold more potent than for its previously known target, silence information regulator 1 and 2 (SIRT1/2). Cambinol decreased tumor necrosis factor-α or interleukin-1 β-induced increases of ceramide and cell death in primary neurons. A preliminary study of cambinol structure and activity allowed the identification of the main structural features required for nSMase2 inhibition. Cambinol and its analogs may be useful as nSMase2 inhibitor tool compounds to prevent ceramide-dependent neurodegeneration.
Figuera-Losada , M , Stathis , M , Dorskind , J M , Thomas , A G , Bandaru , V V R , Yoo , S-W , Westwood , N J , Rogers , G W , McArthur , J C , Haughey , N J , Slusher , B S & Rojas , C 2015 , ' Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties ' PLoS One , vol 10 , no. 5 , e0124481 . DOI: 10.1371/journal.pone.0124481
© 2015 Figuera-Losada et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
This work was supported by National Institute of Mental Health grants: P30 MH075673-06 to BSS, CR, NJH and JCM; R01 MH096636 and R01 MH077542 to NJH (http://projectreporter.nih.gov/reporter.cfm); and The Johns Hopkins Brain Science Institute to BSS.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.